| Literature DB >> 21245014 |
Milou M L Dingemans1, Martin van den Berg, Remco H S Westerink.
Abstract
BACKGROUND/Entities:
Mesh:
Substances:
Year: 2011 PMID: 21245014 PMCID: PMC3223008 DOI: 10.1289/ehp.1003035
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Individual PBDEs discussed in this review.
| Table 1. Individual PBDEs discussed in this review. | ||
| Abbreviation | Name | |
| BDE-47 | 2,2´,4,4´-Tetrabrominated diphenyl ether | |
| BDE-49 | 2,2´,4,5´-Tetrabrominated diphenyl ether | |
| BDE-99 | 2,2´,4,4´,5-Pentabrominated diphenyl ether | |
| BDE-100 | 2,2´,4,4´,6-Pentabrominated diphenyl ether | |
| BDE-153 | 2,2´,4,4´,5,5´-Hexabrominated diphenyl ether | |
| BDE-183 | 2,2´,3,4,4´,5´,6-Heptabrominated diphenyl ether | |
| BDE-203 | 2,2´,3,4,4´,5,5´,6-Octabrominated diphenyl ether | |
| BDE-206 | 2,2´,3,3´,4,4´,5,5´,6-Nonabrominated diphenyl ether | |
| BDE-209 | 2,2´,3,3´,4,4´,5,5´,6,6´-Decabrominated diphenyl ether | |
| DE-71 | Commercial pentaBDE product | |
| 6-MeO-BDE-47 | 6-Methoxy-2,2´,4,4´-tetrabrominated diphenyl ether | |
| 6-OH-BDE-47 | 6-Hydroxy-2,2´,4,4´-tetrabrominated diphenyl ether | |
Effects and effect concentrations of BDE-47, 6-OH-BDE-47, and 6-MeO-BDE-47.
| Table 2. Effects and effect concentrations of BDE-47, 6-OH-BDE-47, and 6-MeO-BDE-47. | ||||||||||
| Effect concentration (μM) | ||||||||||
| Test system (study) | Effect | Exposure duration | BDE-47 | 6-OH-BDE-47 | 6-MeO-BDE-47 | |||||
| Human hepatoma (HepG2) cells (An et al. 2010) | Reduced cell viability | LOEC (72 hr) | — | 0.5 | 5 | |||||
| Cell cycle block | LOEC (48 hr) | — | 0.5 | NE (≤ 5) | ||||||
| ROS generation | LOEC (24 hr) | — | 0.1 | 2 | ||||||
| Human adrenocortical carcinoma (H296R) cells (Cantón et al. 2005, 2006) | Reduced cell viability | LOEC (24 hr) | NE (≤ 7.5) | 2.5 | NE (≤ 7.5) | |||||
| Aromatase activity inhibition | LOEC (24 hr) | NE (≤ 7.5) | 2.5 | 5 | ||||||
| CYP17 activity inhibition | LOEC (24 hr) | NE (≤ 10) | 1 | 10 | ||||||
| Human adrenocortical carcinoma (H296R) cells (Song et al. 2008) | Reduced cell viability | LOEC (48 hr) | NE (≤ 0.5) | NE (≤ 0.5) | NE (≤ 0.5) | |||||
| Aromatase activity inhibition | LOEC (48 hr) | NE (≤ 0.5) | NE (≤ 0.5) | NE (≤ 0.5) | ||||||
| Human placental microsomes (Cantón et al. 2008) | Aromatase activity inhibition | IC50 (40 min) | — | 7.44 | NE (≤ 40) | |||||
| Nuclear hormone receptors transfected in CALUX cell lines (Hamers et al. 2006) | AhR | EC50 (24 hr) | NE (≤ 10) | 1.3 ± 0.4 | — | |||||
| AhR | IC50 (24 hr) | 2.7 ± 0.7 | NE (≤ 10) | — | ||||||
| Androgen receptor | IC50 (24 hr) | 1.0 ± 0.2 | 2.8 ± 0.4 | — | ||||||
| Progesterone receptor | IC50 (24 hr) | > 15 | 5.0 ± 0.9 | — | ||||||
| Estrogen receptor | EC50 (24 hr) | 12 ± 4 | NE (≤ 12.5) | — | ||||||
| Estrogen receptor | IC50 (24 hr) | NE (≤ 12.5) | 0.45 ± 0.03 | — | ||||||
| Human TTR (Hamers et al. 2006) | TTR binding (T4 competition) | IC50 (binding equilibrium) | > 25 | 0.18 | — | |||||
| Human TTR (Marchesini et al. 2008) | TTR binding (T4 competition; biosensor) | IC50 (binding equilibrium) | NR (≤ 1) | 0.087 | NR (1.8) | |||||
| Human TBG (Marchesini et al. 2008) | TBG binding (T4 competition; biosensor) | IC50 (binding equilibrium) | NR (≤ 10) | 0.11 | NR (10) | |||||
| Zebrafish (van Boxtel et al. 2008) | Abnormal development | EC50 (72 hr) | NE (≤ 10) | 0.025 | NE (≤ 10) | |||||
| Mortality (adult) | EC50 (96 hr) | NE (≤ 0.5) | 0.3 | — | ||||||
| Neurotransmitter receptors expressed in | GABAA-receptor full agonism | LOEC (20 sec) | NE (≤ 10) | 10 | — | |||||
| GABAA-receptor partial agonism | LOEC (10 sec) | NE (≤ 10) | 10 | — | ||||||
| nACh-receptor antagonism | LOEC (5 sec) | NE (≤ 10) | 10 | — | ||||||
| Rat PC12 cells (Dingemans et al. 2010a) | Induction of [Ca2+] | LOEC (20 min) | 2 | 0.2 | NE (≤ 20) | |||||
| Ca2+ release from intracellular stores | LOEC (20 min) | NE (≤ 20) | 1 | NE (≤ 20) | ||||||
| Abbreviations: —, not investigated; EC50, half-maximal effect concentration; GABAA, γ‑aminobutyric acid‑A; IC50, half-maximal inhibitory concentration; LOEC, lowest observed effect concentration; nACh, nicotinic acetylcholine; NE, no effect; NR, not reached; ROS, reactive oxygen species; TBG, T4-binding globulin. | ||||||||||
Effects of PBDE exposure on brain structure in rodents after oral administration during PNDs 1–14.
| Table 3. Effects of PBDE exposure on brain structure in rodents after oral administration during PNDs 1–14. | ||||||||
| Species | Effect | PBDE | Effect concentration (μmol/kg body weight) | Reference | ||||
| C57Bl/6 mouse | Decreased GluR subunit NR2B, GluR subunit GluR1, and p286-αCaMKII in hippocampal PSD (Western blot) | BDE-47 | 14 | Dingemans et al. 2007 | ||||
| NMRI mouse | Decreased nAChR (decreased 3H-α-bungarotoxin binding) | BDE-99 | 21 | Viberg et al. 2004 | ||||
| NMRI mouse | Decreased nAChR (decreased 3H-α-bungarotoxin binding) | BDE-99 | 14 | Viberg et al. 2002 | ||||
| NMRI mouse | Alteration in hippocampal proteins (mainly proteins involved in metabolism and energy production, and in striatal proteins (mainly proteins involved in neurodegeneration and neuroplasticity; proteomics) | BDE-99 | 21 | Alm et al. 2006 | ||||
| NMRI mouse | Alteration in cortical proteins (mainly cytoskeletal related; proteomics) | BDE-99 | 21 | Alm et al. 2008 | ||||
| NMRI mouse | Decreased nAChR (decreased 3H-α-bungarotoxin binding) | BDE-153 | 14 | Viberg et al. 2003 | ||||
| NMRI mouse | Increased CaMKII and synaptophysin in hippocampus | BDE-203 | 21 | Viberg 2009a | ||||
| NMRI mouse | Increased CaMKII and synaptophysin in hippocampus | BDE-206 | 21 | Viberg 2009a | ||||
| Sprague-Dawley rat | Decreased nAChR (hypoactive | BDE-209 | 21 | Viberg et al. 2007 | ||||
| NMRI mouse | Decreased nAChR (hypoactive | BDE-209 | 14 | Johansson et al. 2008 | ||||
| NMRI mouse | Decreased BDNF and increased CaMKII and GAP-43 in hippocampus, decreased GAP-43 in cortex | BDE-209 | 21 | Viberg et al. 2008 | ||||
| NMRI mouse | Increased synaptophysin in hippocampus | BDE-209 | 21 | Viberg 2009b | ||||
| Abbreviations: BDNF, brain-derived neurotrophic factor; CaMKII, Ca2+/calmodulin-dependent protein kinase II; GAP-43, growth-associated protein-43; GluR, glutamate receptor; nAChR, nACh receptor; p286-αCaMKII, autophosphorylated-active Ca2+/calmodulin-dependent protein kinase II; PSD, postsynaptic density. | ||||||||
Figure 1Direct and indirect PBDE-induced developmental neurotoxicity. Observed end points for which larger effects have been detected for OH-PBDEs are shown in blue.